Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.
Combining our proven clinical expertise in hemophilia gene therapy and care of bleeding disorders with our research expertise to solidify Children’s Hospital of Philadelphia as the premier center for the therapeutic development and advanced clinical care of inherited bleeding disorders.
Our team at the Congenital Hyperinsulinism Center at CHOP is working on a research study to determine whether an experimental gene therapy product, DTX401, is safe and effective in people with glycogen storage disease type Ia (GSDIa)
This Shifting Perspectives study explores whether we can improve treatment outcomes in teens with anorexia nervosa by adding Adolescent Focused Cognitive Remediation Therapy (CRT) to Family Based Treatment (FBT). CRT focuses on improving cognitive and behavioral flexibility in adolescents.
The purpose of this study is to look at the safety and tolerability (how well you will react) of the study drug (HM15136) and to determine if it is effective for the treatment of Congenital Hyperinsulinism (HI).
The Clinical In Vivo Gene Therapy group supports the development and conduct of in vivo gene and molecular therapy trials at CHOP, as well as the implementation of these novel molecular therapies into the clinic post licensure.